Revenue Estimates Analysis of Conatus Pharmaceuticals Inc.(NASDAQ:CNAT): Gap, Inc. (The)(NYSE:GPS)

0
0

Conatus Pharmaceuticals Inc. (CNAT) will report its next earnings on Nov 07 AMC. The company reported the earnings of $-0.1/Share in the last quarter where the estimated EPS by analysts was $-0.12/share. The difference between the expected and actual EPS was $0.02/share, which represents an Earnings surprise of 16.7%.

Many analysts are providing their Estimated Earnings analysis for Conatus Pharmaceuticals Inc. and for the current quarter 1 analysts have projected that the stock could give an Average Earnings estimate of $-0.09/share. These analysts have also projected a Low Estimate of $-0.09/share and a High Estimate of $-0.09/share.

In case of Revenue Estimates, 1 analysts have provided their consensus Average Revenue Estimates for Conatus Pharmaceuticals Inc. as 6 Million. According to these analysts, the Low Revenue Estimate for Conatus Pharmaceuticals Inc. is 6 Million and the High Revenue Estimate is 6 Million. The company had Year Ago Sales of 7.41 Million.

Some buy side analysts are also providing their Analysis on Conatus Pharmaceuticals Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Conatus Pharmaceuticals Inc. might touch $1.5 high while the Average Price Target and Low price Target is $1.5 and $1.5 respectively.

Conatus Pharmaceuticals Inc. closed its last trading session at $0.35 with the loss of -4.23%. The Market Capitalization of the company stands at 11.28 Million. The Company has 52-week high of $5.79 and 52-week low of $0.25. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.95% where SMA50 and SMA200 are -0.88% and -62.02% respectively. The Company Touched its 52-Week High on 11/08/18 and 52-Week Low on 06/27/19.

The Relative Volume of the company is 0.41 and Average Volume (3 months) is 683.53 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -30%. The Return on Equity (ROE) value stands at -60.6%. While it’s Return on Investment (ROI) value is -66.7%.

While looking at the Stock’s Performance, Conatus Pharmaceuticals Inc. currently shows a Weekly Performance of 0%, where Monthly Performance is 4.58%, Quarterly performance is 12.43%, 6 Months performance is -61.05% and yearly performance percentage is -93.44%. Year to Date performance value (YTD perf) value is -80.35%. The Stock currently has a Weekly Volatility of 4.76% and Monthly Volatility of 6.53%.

Gap, Inc. (The) (GPS) will report its next earnings on Nov 19 AMC. The company reported the earnings of $0.63/Share in the last quarter where the estimated EPS by analysts was $0.53/share. The difference between the expected and actual EPS was $0.1/share, which represents an Earnings surprise of 18.9%.

Many analysts are providing their Estimated Earnings analysis for Gap, Inc. (The) and for the current quarter 20 analysts have projected that the stock could give an Average Earnings estimate of $0.55/share. These analysts have also projected a Low Estimate of $0.51/share and a High Estimate of $0.59/share.

These analysts also forecasted Growth Estimates for the Current Quarter for GPS to be -20.3%. They are projecting Next Quarter growth of -8.33%. For the next 5 years, Gap, Inc. (The) is expecting Growth of 1.12% per annum, whereas in the past 5 years the growth was -20.46% per annum.

Some buy side analysts are also providing their Analysis on Gap, Inc. (The), where 0 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 3 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Gap, Inc. (The) might touch $37 high while the Average Price Target and Low price Target is $18.95 and $14 respectively.

Gap, Inc. (The) closed its last trading session at $17.73 with the gain of 1.86%. The Market Capitalization of the company stands at 6.51 Billion. The Company has 52-week high of $31.39 and 52-week low of $15.11. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.65% where SMA50 and SMA200 are 4.98% and -13.71% respectively. The Company Touched its 52-Week High on 03/01/19 and 52-Week Low on 09/03/19.

The Relative Volume of the company is 0.54 and Average Volume (3 months) is 7.62 million. The company’s P/E (price to earnings) ratio is 7.11 and Forward P/E ratio of 8.68.

The company shows its Return on Assets (ROA) value of 8.5%. The Return on Equity (ROE) value stands at 26.4%. While it’s Return on Investment (ROI) value is 22.4%.

While looking at the Stock’s Performance, Gap, Inc. (The) currently shows a Weekly Performance of 11.07%, where Monthly Performance is 11%, Quarterly performance is 1.4%, 6 Months performance is -25.86% and yearly performance percentage is -35.18%. Year to Date performance value (YTD perf) value is -29.89%. The Stock currently has a Weekly Volatility of 3.03% and Monthly Volatility of 3.25%.

SHARE